Fenofibrate and losartan

Fenofibrate and losartan.

Fenofibrate and losartan.

Tan et al recently described a case of ''resistant giant cell arteritis'' successfully treated with etanercept. 1 Their patient, who had classical symptoms of polymyalgia rheu-matica (PMR), developed headaches while receiving low dose steroids. Biopsy of a temporal artery showed no arteritis. Because giant cell arteritis (GCA) was suspected on clinical grounds, high dose steroids were institute...

Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.

OBJECTIVE To assess the effect of a combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism in hypertriglyceridaemic and/or hypertensive patients with gout. METHODS Twenty seven patients with gout were included in a fenofibrate plus anti-hyperuricaemic agents combination study, and 25 in a losartan plus anti-hyperuricaemic agents combina...

Fenofibrate and metabolic syndrome.

The fibric acid derivative, fenofibrate (FF) has been used in the US since 1998 to manage patients with dyslipidemia. Typical changes in serum lipids as result a of FF treatment include clinically important mean reductions of serum triglycerides (TG) by a mean change of -93.7 mg/dL (-39.3%), increases of high density lipoprotein cholesterol (HDLC) by +5.5 mg/dL (+12.4%), and reductions in low d...

Fenofibrate, statins, and inflammation.

To the Editor: I recently read the review by Berg et al, about tissue, inflammation, and cardiovascular disease.1 Although the review discusses our research on ligands for peroxisome proliferator activated receptor (PPAR), we used fenofibrate, a PPARactivator, not glitazones, PPARagonists, as the review suggests.2 We also found that statins non-significantly lower serum adiponectin levels, not ...